Yue Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yue Zheng has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Huangdong Dai
Co-first authors
4 shared publications- Liang Zhao
Department of Cardiology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, China
2 shared publications Naishi Zhao
Co-first authors
2 shared publicationsHao Wang
Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Road, Shanghai, China
1 shared publicationHua Liu
Department of Cardiovascular Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
1 shared publicationJindong Chen
Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Road, Shanghai, China
1 shared publication
Latest Publications
- 6 April 2022
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 80 (1) , 132-139
CircLDLR Modulates the Proliferation and Apoptosis of Vascular Smooth Muscle Cells in Coronary Artery Disease Through miR-26-5p/KDM6A Axis
The purpose of this study was to investigate the effect of circLDLR on the proliferation and apoptosis of vascular smooth muscle cells (VSMCs) in coronary artery disease and its regulatory mechanism. The expression of KDM6A was detected by qRT-PCR or Western blot. VSMCs were transfected with miR-26-5p mimic/inhibitor or OE KDM6A. Cell proliferation and apoptosis were assessed. Luciferase reporter gene assays were used to examine interactions between miR-26-5p and KDM6A in VSMCs. Downregulation of circLDLR was associated with increased miR-26-5p in coronary artery disease tissues. In addition, circLDLR could inhibit cell proliferation and promote cell apoptosis by regulating miR-26-5p. Moreover, the overexpression of KDM6A reduced VSMCs proliferation and increased apoptosis in an miR-26-5p/circLDLR axis–dependent manner. CircLDLR modulates the proliferation and apoptosis of VSMCs through miR-26-5p/KDM6A axis.
- 6 April 2022
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 80 (1) , 132-139
CircLDLR Modulates the Proliferation and Apoptosis of Vascular Smooth Muscle Cells in Coronary Artery Disease Through miR-26-5p/KDM6A Axis
The purpose of this study was to investigate the effect of circLDLR on the proliferation and apoptosis of vascular smooth muscle cells (VSMCs) in coronary artery disease and its regulatory mechanism. The expression of KDM6A was detected by qRT-PCR or Western blot. VSMCs were transfected with miR-26-5p mimic/inhibitor or OE KDM6A. Cell proliferation and apoptosis were assessed. Luciferase reporter gene assays were used to examine interactions between miR-26-5p and KDM6A in VSMCs. Downregulation of circLDLR was associated with increased miR-26-5p in coronary artery disease tissues. In addition, circLDLR could inhibit cell proliferation and promote cell apoptosis by regulating miR-26-5p. Moreover, the overexpression of KDM6A reduced VSMCs proliferation and increased apoptosis in an miR-26-5p/circLDLR axis–dependent manner. CircLDLR modulates the proliferation and apoptosis of VSMCs through miR-26-5p/KDM6A axis.
- Open Access
- 25 February 2022
- Published by Taylor & Francis in Bioengineered
- Vol. 13 (3) , 5987-5998
Circular RNA hsa_circ_0008896 accelerates atherosclerosis by promoting the proliferation, migration and invasion of vascular smooth muscle cells via hsa-miR-633/CDC20B (cell division cycle 20B) axis
Circular RNAs, a class of circularly closed non-coding RNAs, play essential roles in the formation of atherosclerosis, which is a frequent cause of cardiovascular and cerebrovascular diseases. Although many circular RNAs are found to be involved in the progression of atherosclerosis, more circular RNA regulators still need to be identified, to improve the understanding of the regulatory networks of atherosclerosis. Here, we found that hsa_circ_0008896 was significantly up-regulated in both in vitro and in vivo atherosclerosis models, indicating hsa_circ_0008896 was involved in the progression of atherosclerosis. Further functional analyses confirmed that knockdown of hsa_circ_0008896 decreased proliferation, migration, and invasion of VSMCs. In addition, we conducted bioinformatics analysis and found that hsa-miR-633 could directly bind to hsa_circ_0008896, which was confirmed by RNA immune-precipitation (RIP) assays. Results of proliferation, migration, and invasion assays showed that hsa-miR-633 inhibitor reversed the si-circ_0008896 phenotypes, indicating that hsa_circ_0008896 functionally bound to hsa-miR-633. At last, combining bioinformatics and experimental analyses, we found the protein target of hsa_circ_0008896/hsa-miR-633, CDC20B (cell division cycle 20B). The expression level of CDC20B was regulated by hsa-miR-633, and knockdown of CDC20B decreased proliferation, migration, and invasion of VSMCs. Taken together, hsa_circ_0008896 regulated the expression of CDC20B by sponging hsa-miR-633, and then enhanced proliferation, migration, and invasion of VSMCs to promote the progression of atherosclerosis. Graphical Abstract
- 25 February 2022
- Published by Taylor & Francis in Bioengineered
- Vol. 13 (3) , 5987-5998
Open AccessCircular RNA hsa_circ_0008896 accelerates atherosclerosis by promoting the proliferation, migration and invasion of vascular smooth muscle cells via hsa-miR-633/CDC20B (cell division cycle 20B) axis
Circular RNAs, a class of circularly closed non-coding RNAs, play essential roles in the formation of atherosclerosis, which is a frequent cause of cardiovascular and cerebrovascular diseases. Although many circular RNAs are found to be involved in the progression of atherosclerosis, more circular RNA regulators still need to be identified, to improve the understanding of the regulatory networks of atherosclerosis. Here, we found that hsa_circ_0008896 was significantly up-regulated in both in vitro and in vivo atherosclerosis models, indicating hsa_circ_0008896 was involved in the progression of atherosclerosis. Further functional analyses confirmed that knockdown of hsa_circ_0008896 decreased proliferation, migration, and invasion of VSMCs. In addition, we conducted bioinformatics analysis and found that hsa-miR-633 could directly bind to hsa_circ_0008896, which was confirmed by RNA immune-precipitation (RIP) assays. Results of proliferation, migration, and invasion assays showed that hsa-miR-633 inhibitor reversed the si-circ_0008896 phenotypes, indicating that hsa_circ_0008896 functionally bound to hsa-miR-633. At last, combining bioinformatics and experimental analyses, we found the protein target of hsa_circ_0008896/hsa-miR-633, CDC20B (cell division cycle 20B). The expression level of CDC20B was regulated by hsa-miR-633, and knockdown of CDC20B decreased proliferation, migration, and invasion of VSMCs. Taken together, hsa_circ_0008896 regulated the expression of CDC20B by sponging hsa-miR-633, and then enhanced proliferation, migration, and invasion of VSMCs to promote the progression of atherosclerosis. Graphical Abstract
- Open Access
- 25 June 2021
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 25 (16) , 8028-8038
Circ_0002984 induces proliferation, migration and inflammation response of VSMCs induced by ox‐LDL through miR‑326‐3p/VAMP3 axis in atherosclerosis
Atherosclerosis can result in multiple cardiovascular diseases. Circular RNAs (CircRNAs) have been reported as significant non‐coding RNAs in atherosclerosis progression. Dysfunction of vascular smooth muscle cells (VSMCs) is involved in atherosclerosis. However, up to now, the effect of circ_0002984 in atherosclerosis is still unknown. Currently, we aimed to investigate the function of circ_0002984 in VSMCs incubated by oxidized low‐density lipoprotein (ox‐LDL). Firstly, our findings indicated that the expression levels of circ_0002984 were significantly up‐regulated in the serum of atherosclerosis patients and ox‐LDL‐incubated VSMCs. Loss of circ_0002984 suppressed VSMC viability, cell cycle distribution and migration capacity. Then, we carried out ELISA assay to determine TNF‐α and IL‐6 levels. The data implied that lack of circ_0002984 obviously repressed ox‐LDL–stimulated VSMC inflammation. Meanwhile, miR‐326‐3p, which was predicted as a target of circ_0002984, was obviously down‐regulated in VSMCs treated by ox‐LDL. Additionally, after overexpression circ_0002984 in VSMCs, a decrease in miR‐326‐3p was observed. Subsequently, miR‐326‐3p was demonstrated to target vesicle‐associated membrane protein 3 (VAMP3). Therefore, we hypothesized that circ_0002984 could modulate expression of VAMP3 through sponging miR‐326‐3p. Furthermore, we confirmed that up‐regulation of miR‐326‐3p rescued the circ_0002984 overexpressing‐mediated effects on VMSC viability, migration and inflammation. Additionally, miR‐326‐3p inhibitor‐mediated functions on VSMCs were reversed by knockdown of VAMP3. In conclusion, circ_0002984 mediated cell proliferation, migration and inflammation through modulating miR‐326‐3p and VAMP3 in VSMCs, which suggested that circ_0002984 might hold great promise as a therapeutic strategy for atherosclerosis.
- 25 June 2021
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 25 (16) , 8028-8038
Open AccessCirc_0002984 induces proliferation, migration and inflammation response of VSMCs induced by ox‐LDL through miR‑326‐3p/VAMP3 axis in atherosclerosis
Atherosclerosis can result in multiple cardiovascular diseases. Circular RNAs (CircRNAs) have been reported as significant non‐coding RNAs in atherosclerosis progression. Dysfunction of vascular smooth muscle cells (VSMCs) is involved in atherosclerosis. However, up to now, the effect of circ_0002984 in atherosclerosis is still unknown. Currently, we aimed to investigate the function of circ_0002984 in VSMCs incubated by oxidized low‐density lipoprotein (ox‐LDL). Firstly, our findings indicated that the expression levels of circ_0002984 were significantly up‐regulated in the serum of atherosclerosis patients and ox‐LDL‐incubated VSMCs. Loss of circ_0002984 suppressed VSMC viability, cell cycle distribution and migration capacity. Then, we carried out ELISA assay to determine TNF‐α and IL‐6 levels. The data implied that lack of circ_0002984 obviously repressed ox‐LDL–stimulated VSMC inflammation. Meanwhile, miR‐326‐3p, which was predicted as a target of circ_0002984, was obviously down‐regulated in VSMCs treated by ox‐LDL. Additionally, after overexpression circ_0002984 in VSMCs, a decrease in miR‐326‐3p was observed. Subsequently, miR‐326‐3p was demonstrated to target vesicle‐associated membrane protein 3 (VAMP3). Therefore, we hypothesized that circ_0002984 could modulate expression of VAMP3 through sponging miR‐326‐3p. Furthermore, we confirmed that up‐regulation of miR‐326‐3p rescued the circ_0002984 overexpressing‐mediated effects on VMSC viability, migration and inflammation. Additionally, miR‐326‐3p inhibitor‐mediated functions on VSMCs were reversed by knockdown of VAMP3. In conclusion, circ_0002984 mediated cell proliferation, migration and inflammation through modulating miR‐326‐3p and VAMP3 in VSMCs, which suggested that circ_0002984 might hold great promise as a therapeutic strategy for atherosclerosis.
- Open Access
- 15 April 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
LncRNA Nuclear-Enriched Abundant Transcript 1 Regulates Atrial Fibrosis via the miR-320/NPAS2 Axis in Atrial Fibrillation
Atrial fibrosis is a key contributor to atrial fibrillation (AF). Long non-coding ribonucleic acids (lncRNAs) were demonstrated to exhibit a key role in fibrotic remodeling; however, the function of nuclear-enriched abundant transcript 1 (NEAT1) in atrial fibrosis remains unclear. In the present study, we showed that NEAT1 was upregulated in atrial tissues of AF patients and was positively related to collagen I (coll I) and collagen III (coll III) expressions. Furthermore, the deletion of NEAT1 attenuated angiotensin II (Ang II)-caused atrial fibroblast proliferation, migration, and collagen production. We further observed that NEAT1 knockdown improved Ang II caused mouse atrial fibrosis in in vivo experiments. Moreover, we demonstrated that NEAT1 could negatively regulate miR-320 expression by acting as a competitive endogenous RNA (ceRNA). miR-320 directly targeted neuronal per arnt sim domain protein 2 (NPAS2) and suppressed its expression. We observed that NEAT1 exerted its function via the miR-320–NPAS2 axis in cardiac fibroblasts. These findings indicate that NEAT1 exerts a significant effect on atrial fibrosis and that this lncRNA is a new potential molecular target for AF treatment.
- 15 April 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessLncRNA Nuclear-Enriched Abundant Transcript 1 Regulates Atrial Fibrosis via the miR-320/NPAS2 Axis in Atrial Fibrillation
Atrial fibrosis is a key contributor to atrial fibrillation (AF). Long non-coding ribonucleic acids (lncRNAs) were demonstrated to exhibit a key role in fibrotic remodeling; however, the function of nuclear-enriched abundant transcript 1 (NEAT1) in atrial fibrosis remains unclear. In the present study, we showed that NEAT1 was upregulated in atrial tissues of AF patients and was positively related to collagen I (coll I) and collagen III (coll III) expressions. Furthermore, the deletion of NEAT1 attenuated angiotensin II (Ang II)-caused atrial fibroblast proliferation, migration, and collagen production. We further observed that NEAT1 knockdown improved Ang II caused mouse atrial fibrosis in in vivo experiments. Moreover, we demonstrated that NEAT1 could negatively regulate miR-320 expression by acting as a competitive endogenous RNA (ceRNA). miR-320 directly targeted neuronal per arnt sim domain protein 2 (NPAS2) and suppressed its expression. We observed that NEAT1 exerted its function via the miR-320–NPAS2 axis in cardiac fibroblasts. These findings indicate that NEAT1 exerts a significant effect on atrial fibrosis and that this lncRNA is a new potential molecular target for AF treatment.
- 19 June 2020
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 51 (1) , 129-135
Long-term left atrial thrombi after mitral valve replacement
The aim of this study was to evaluate the risk factors and characteristics of long-term postoperative left atrial (LA) thrombi after mitral valve replacement. Transthoracic echocardiography (TTE) file of 3117 consecutive patients with mitral valve replacement history was reviewed (between Jan 2006 and Feb 2019). 45 LA thrombi cases (1.4%) was identified and matched to 180 thrombi-free cases by random sampling. The median detection time of LA thrombi was 58 months (IQR, 17–144) after MV replacement. Distribution of LA thrombi included roof (n = 10), posterior wall (n = 9), appendage (n = 7), lateral wall (n = 6), anterior wall (n = 2), septum (n = 1) and multiple site (n = 10). All thrombi were sessile and immobile. The independent predictors for LA thrombi development by stepwise multiple regression analysis were the larger LA size (> 55 mm), the increased of mitral valve pressure gradient (MVPG > 6 mmHg), and the reduced of left ventricular ejection fraction (LVEF < 50%). Long-term thrombi incidence after mitral valve replacement is somewhat low. In individuals with mitral prosthetic valves, larger LA size, increased MVPG and reduced LVEF were three promising independent predictors of the insistence of LA thrombi. Furthermore, LA thrombi were sessile, immobile and widespread in the long-term postoperative period after mitral valve replacement. Close monitoring should be applied in these patients with thrombi risk.
- 19 June 2020
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 51 (1) , 129-135
Long-term left atrial thrombi after mitral valve replacement
The aim of this study was to evaluate the risk factors and characteristics of long-term postoperative left atrial (LA) thrombi after mitral valve replacement. Transthoracic echocardiography (TTE) file of 3117 consecutive patients with mitral valve replacement history was reviewed (between Jan 2006 and Feb 2019). 45 LA thrombi cases (1.4%) was identified and matched to 180 thrombi-free cases by random sampling. The median detection time of LA thrombi was 58 months (IQR, 17–144) after MV replacement. Distribution of LA thrombi included roof (n = 10), posterior wall (n = 9), appendage (n = 7), lateral wall (n = 6), anterior wall (n = 2), septum (n = 1) and multiple site (n = 10). All thrombi were sessile and immobile. The independent predictors for LA thrombi development by stepwise multiple regression analysis were the larger LA size (> 55 mm), the increased of mitral valve pressure gradient (MVPG > 6 mmHg), and the reduced of left ventricular ejection fraction (LVEF < 50%). Long-term thrombi incidence after mitral valve replacement is somewhat low. In individuals with mitral prosthetic valves, larger LA size, increased MVPG and reduced LVEF were three promising independent predictors of the insistence of LA thrombi. Furthermore, LA thrombi were sessile, immobile and widespread in the long-term postoperative period after mitral valve replacement. Close monitoring should be applied in these patients with thrombi risk.